COVID-19 IN INFLAMMATORY BOWEL DISEASE: SHOULD WE BE MORE CAREFUL WITH THE USE OF SALICYLATES?
Authors:
- Mariana Rolim Fernandes MacedoMMMariana Rolim Fernandes Macedo
- Carlos Arthur Fernandes SobreiraCSCarlos Arthur Fernandes Sobreira
- Carola Braz de LavorCLCarola Braz de Lavor
- Camila Ribeiro RôlaCRCamila Ribeiro Rôla
- Ticiana Maria de Lavor RolimTRTiciana Maria de Lavor Rolim
- Francisco Sérgio Rangel de Paula PessoaFPFrancisco Sérgio Rangel de Paula Pessoa
- Milena Santana GirãoMGMilena Santana Girão
- Caio César Furtado FreireCFCaio César Furtado Freire
- Ranna Caroline Bezerra SiebraRSRanna Caroline Bezerra Siebra
- Isabele de Sá Silveira MeloIMIsabele de Sá Silveira Melo
- Marcellus Henrique Loiola Ponte de SouzaMSMarcellus Henrique Loiola Ponte de Souza
- Lucia Libanez Bessa Campelo BragaLBLucia Libanez Bessa Campelo Braga
Open Access
- 1 January 2024
- journal article
- research article
- Published by FapUNIFESP (SciELO) in Arquivos de Gastroenterologia
- Vol. 61, e23195
Abstract
Backgrounds: Fortunately, much has been studied about COVID-19 in patients with inflammatory bowel diseases (IBD). Evidence suggests that these patients do not appear to be at increased risk of severe COVID-19. However, there are still some uncertainties regarding the clinical manifestations of COVID-19 in patients with immune-mediated diseases. Objective: This study aimed to describe the main symptoms of COVID-19 and their frequency in IBD patients and evaluate the impact of the IBD therapeutic drugs on clinical presentation of COVID-19 and to determine factors associated with COVID-19 in this population. Methods: Adult patients with IBD from three tertiary-care public, teaching hospitals in Ceará, Northeastern Brazil, were evaluated during one scheduled appointment from March to December 2020. Patients with possible or confirmed COVID-19 were compared with patients without COVID-19. Furthermore, incidences of each symptom were evaluated based on the use of IBD therapeutic drugs. Results: A total of 515 patients with IBD were included in the study: 234 with CD, and 281 with UC. Of these, 174 patients (34%) had possible/confirmed COVID-19 of whom 156 (90%) were symptomatic. Main symptoms were fever (65%) and headache (65%); gastrointestinal symptoms occurred in one third of patients and were higher than COVID-19 in general population. The factors associated with having COVID-19 were female gender (OR 1.71, 95%CI: 1.17-2.50); contact at home (OR 5.07, 95%CI: 3.31-7.78) and outside the home (OR 3.14, 95%CI: 2.10-4.71) with a case of COVID-19; work outside of the home (OR 1.87, 95%CI: 1.26-2.78); family history of COVID-19 (OR 2.29, 95%CI 1.58-3.33) use of salicylate (OR 1.71, 95%CI: 1.17-4.28); and asthma (OR 7.10, 95%CI: 1.46-34.57). Conclusion: IBD patients at high risk of COVID-19 infection may need to avoid salicylate therapy but further studies are necessary to confirm this association.Keywords
This publication has 31 references indexed in Scilit:
- Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory DiseasesArchivos de Bronconeumología, 2022
- Is COVID-19 Gender-sensitive?Journal of Neuroimmune Pharmacology, 2021
- Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global surveyThe Lancet Gastroenterology & Hepatology, 2020
- Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysisGastroenterology, 2020
- Are there any association between COVID-19 severity and immunosuppressive therapy?Immunology Letters, 2020
- Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City AreaJAMA, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative ColitisInflammatory Bowel Diseases, 2008
- A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITYThe Lancet, 1980